Science Behind GATC-1021 Featured in Physicians Weekly
June 19, 2026 — A new feature in Physician’s Weekly explores the clinical science behind the discovery of GATC-1021, a non-opioid potential treatment targeting opioid addiction. Dr. Christie Fowler of University of California, Irvine’s Department of Neurobiology and Behavior, lead author and researcher for the pre-clinical study on GATC-1021, was interviewed for the article.
To learn how GATC-1021 may allow brain cells to reset to normal levels while reducing cravings—and about the profound clinical and commercial implications of this discovery, please read the full article.
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
GATC Health to Host Business Development Meetings in San Francisco during the Annual J.P. Morgan Healthcare Conference
January 8, 2026—GATC Health today announced that several of its executives will be in San Francisco next week during the annual J.P. Morgan…
Read more
GATC Health Takes the Stage at the DIA Global Annual Meeting—Life Sciences’ Largest Event
June 24, 2026 — Last week at the DIA Global Annual Meeting in Philadelphia, GATC Health President Dr. Rahul Gupta joined an estee…
Read more
GATC Health Publishes a Multi-Omics Exosome Study Defining a New Therapeutic Path in Diabetes
Irvine, CA — May 11, 2026 — GATC Health is announcing the publication of “The Multi-Omics Profiling of Early-Passage Mesenchymal Stem …
Read more